Publications by authors named "Keith Wilcoxen"

Claim this Profile
E
Erratum for Essalmani et al., "Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity".
Rachid Essalmani, Jaspreet Jain, Delia Susan-Resiga, Ursula Andréo, Alexandra Evagelidis, Keith Wilcoxen

J Virol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A highly selective, cell-permeable furin inhibitor BOS-318 rescues key features of cystic fibrosis airway disease.
Lisa E J Douglas, James A Reihill, Melisa W Y Ho, Jeffrey M Axten, Nino Campobasso, Keith M Wilcoxen

Cell Chem Biol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
Rachid Essalmani, Jaspreet Jain, Delia Susan-Resiga, Ursula Andréo, Alexandra Evagelidis, Keith Wilcoxen

J Virol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme.
Matthew M Hamilton, Faika Mseeh, Timothy J McAfoos, Paul G Leonard, Naphtali J Reyna, Keith Wilcoxen

J Med Chem· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R.
Barbara Czako, Joseph R Marszalek, Jason P Burke, Pijus Mandal, Paul G Leonard, Keith Wilcoxen

J Med Chem· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.
Ádám Póti, Kinga Berta, Yonghong Xiao, Orsolya Pipek, Gregory T Klus, Keith Wilcoxen

Br J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
Gayathri Srinivasan, Gurjit Singh Sidhu, Elizabeth A Williamson, Aruna S Jaiswal, Nasreen Najmunnisa, Keith Wilcoxen

Cancer Chemother Pharmacol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
Mariam M AlHilli, Marc A Becker, S John Weroha, Karen S Flatten, Rachel M Hurley, Keith M Wilcoxen

Gynecol Oncol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.
Philip Jones, Keith Wilcoxen, Michael Rowley, Carlo Toniatti

J Med Chem· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel drugs for promising targets.
Robert E Martell, David G Brooks, Yan Wang, Keith Wilcoxen

Clin Ther· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intersectional innovation in biomarker development for patient-centric medicine.
Keith M Wilcoxen, Jacob Hesterman, Kelly Davis Orcutt, Jack Hoppin

Per Med· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical metabolomics in drug discovery.
Keith M Wilcoxen, Taisuke Uehara, Khin Than Myint, Yoshiaki Sato, Yoshiya Oda

Expert Opin Drug Discov· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances of MEK inhibitors and their clinical progress.
John Yuan Wang, Keith M Wilcoxen, Kenichi Nomoto, Sara Wu

Curr Top Med Chem· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional and mechanistic analyses of biomimetic aminoacyl transfer reactions in de novo designed coiled coil peptides via rational active site engineering.
Luke J Leman, Dana A Weinberger, Zheng-Zheng Huang, Keith M Wilcoxen, M Reza Ghadiri

J Am Chem Soc· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomimetic catalysis of intermodular aminoacyl transfer.
Keith M Wilcoxen, Luke J Leman, Dana A Weinberger, Zheng-Zheng Huang, M Reza Ghadiri

J Am Chem Soc· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral cyclic D,L-alpha-peptides: targeting a general biochemical pathway in virus infections.
W Seth Horne, Christopher M Wiethoff, Chunli Cui, Keith M Wilcoxen, Manuel Amorin

Bioorg Med Chem· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
Chen Chen, Keith M Wilcoxen, Charles Q Huang, Yun-Feng Xie, James R McCarthy

J Med Chem· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.
Charles Q Huang, Keith M Wilcoxen, Dimitri E Grigoriadis, James R McCarthy, Chen Chen

Bioorg Med Chem Lett· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility.
Chen Chen, Keith M Wilcoxen, Charles Q Huang, James R McCarthy, Takung Chen

Bioorg Med Chem Lett· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of 3-phenylpyrazolo[4,3-b]pyridines via a convenient synthesis of 4-amino-3-arylpyrazoles and SAR of corticotropin-releasing factor receptor type-1 antagonists.
Keith Wilcoxen, Charles Q Huang, James R McCarthy, Dimitri E Grigoriadis, Chen Chen

Bioorg Med Chem Lett· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of 1-methyl-3-phenylpyrazolo[4,3-b]pyridines via a methylation of 4-phthalimino-3-phenylpyrazoles and optimization toward highly potent corticotropin-releasing factor type-1 antagonists.
Charles Q Huang, Keith Wilcoxen, James R McCarthy, Mustaph Haddach, Dimitri Grigoriadis

Bioorg Med Chem Lett· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR of 8-arylquinolines as potent corticotropin-releasing factor1 (CRF1) receptor antagonists.
Charles Q Huang, Keith Wilcoxen, James R McCarthy, Mustapha Haddach, Thomas R Webb

Bioorg Med Chem Lett· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automated mass spectrometric sequence determination of cyclic peptide library members.
James E Redman, Keith M Wilcoxen, M Reza Ghadiri

J Comb Chem· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
6
6,7-dihydroxyisoquinoline-3-carboxylic acids are potent inhibitors on the binding of insulin-like growth factor (IGF) to IGF-binding proteins: optimization of the 1-position benzoyl side chain.
Yun-Fei Zhu, Keith Wilcoxen, Timothy Gross, Patrick Connors, Nathalie Strack

Bioorg Med Chem Lett· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quinoline-carboxylic acids are potent inhibitors that inhibit the binding of insulin-like growth factor (IGF) to IGF-binding proteins.
Yun-Fei Zhu, Xiao-Chuan Wang, Patrick Connors, Keith Wilcoxen, Yinghong Gao

Bioorg Med Chem Lett· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis